- Home
- CNTA vs SDGR Comparison
CNTA vs SDGR Comparison
Compare CNTA & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNTA
- SDGR
- Stock Information
- Founded
- CNTA 2020
- SDGR 1990
- Country
- CNTA United Kingdom
- SDGR United States
- Employees
- CNTA N/A
- SDGR N/A
- Industry
- CNTA Biotechnology: Pharmaceutical Preparations
- SDGR Biotechnology: Pharmaceutical Preparations
- Sector
- CNTA Health Care
- SDGR Health Care
- Exchange
- CNTA Nasdaq
- SDGR Nasdaq
- Market Cap
- CNTA 2.2B
- SDGR 1.8B
- IPO Year
- CNTA 2021
- SDGR 2020
- Fundamental
- Price
- CNTA $16.63
- SDGR $22.64
- Analyst Decision
- CNTA Strong Buy
- SDGR Buy
- Analyst Count
- CNTA 8
- SDGR 9
- Target Price
- CNTA $23.00
- SDGR $32.11
- AVG Volume (30 Days)
- CNTA 964.8K
- SDGR 1.0M
- Earning Date
- CNTA 03-27-2025
- SDGR 02-26-2025
- Dividend Yield
- CNTA N/A
- SDGR N/A
- EPS Growth
- CNTA N/A
- SDGR N/A
- EPS
- CNTA N/A
- SDGR N/A
- Revenue
- CNTA $6,853,000.00
- SDGR $193,348,000.00
- Revenue This Year
- CNTA N/A
- SDGR N/A
- Revenue Next Year
- CNTA N/A
- SDGR $31.43
- P/E Ratio
- CNTA N/A
- SDGR N/A
- Revenue Growth
- CNTA N/A
- SDGR N/A
- 52 Week Low
- CNTA $7.75
- SDGR $16.67
- 52 Week High
- CNTA $19.09
- SDGR $33.63
- Technical
- Relative Strength Index (RSI)
- CNTA 48.19
- SDGR 43.67
- Support Level
- CNTA $15.50
- SDGR $23.14
- Resistance Level
- CNTA $18.55
- SDGR $28.47
- Average True Range (ATR)
- CNTA 1.25
- SDGR 1.60
- MACD
- CNTA -0.12
- SDGR -0.34
- Stochastic Oscillator
- CNTA 31.57
- SDGR 9.19
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include 1) SerpinPC for Hemophilia A, B, 2) LB101 for Solid Tumors, 3) ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders, 4) MGX292 Pulmonary Arterial Hypertension (PAH) and 5) Undisclosed for Solid Tumors.
About SDGR Schrodinger Inc.
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.